Regulatory Milestone Designed to Expedite Path to FDA Clearance and CMS Coverage. Sunnyvale, Calif., November 28, 2023 — Inflammatix, Inc., a pioneering molecular diagnostics company, announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s lead product, the TriVerity™ Acute Infection and Sepsis Test System. The TriVerity [...]

Company Reaches Important Product Development Milestone with its Myrna™ Instrument and TriVerity Cartridge. Sunnyvale, Calif., November 15, 2023  — Inflammatix, Inc., a pioneering molecular diagnostics company, announced today that the company has completed technical development for its TriVerity™ Acute Infection and Sepsis Test System, which includes the Myrna™ Instrument, and for the TriVerity™ Cartridge. TriVerity is [...]

Data-biobank Acutelines and Inflammatix, an innovative molecular diagnostics company, are joining forces to improve the early detection of sepsis: a potentially fatal syndrome caused by a dysregulated immune response to infection. Sunnyvale, Calif., September 13, 2023  --- Acutelines and Inflammatix are developing a smart tool to facilitate recognition of sepsis and support clinical decisions in the [...]

Sunnyvale, Calif., July 10, 2023  --- Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Heiner Dreismann, PhD, as a member of the company’s board of directors. Dr. Dreismann brings to Inflammatix more than 35 years of experience in the life sciences and health care industries and is regarded as a pioneer in [...]

Burlingame, Calif., June 15, 2022  --- Inflammatix, Inc., a pioneering molecular diagnostics company, announced today the appointment of Purvesh Khatri, PhD, as Chief Scientific Officer. As a co-founder of Inflammatix, Dr. Khatri had previously served as a Scientific Advisor to the company while serving as Associate Professor at Stanford University’s Institute for Immunity, Transplantation, and [...]

Burlingame, Calif., November 30, 2021  --- Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company’s board of directors. Dr. Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on [...]

Third Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of Care Burlingame, Calif., November 18, 2021  --- Inflammatix, a pioneering molecular diagnostics company, announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department [...]

Funding Will Support Groundbreaking Development of Sepsis Endotypes Test Burlingame, Calif., November 11, 2021  --- Inflammatix, a pioneering molecular diagnostics company, announced today that the National Institute of General Medical Sciences, part of the National Institutes of Health, has awarded the company a Small Business Innovation Research (NIH SBIR) Direct-to-Phase II grant of $1.7 million. [...]

Burlingame, Calif., March 16, 2021  --- Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, [...]

Second Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of Care Burlingame, Calif., October 29, 2020  --- Inflammatix a pioneering molecular diagnostics company, announced today a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of [...]